Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Final Word on Diet-Breast Cancer Link Must Come From Clinical Trials: WHI

March 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

BETHESDA, Md--Concerned that a New England Journal of Medicine article reporting no link between fat intake and breast cancer might deter women from joining the diet-cancer segment of the NIH-sponsored Women's Health Initiative (WHI), its top leaders took an unusual step.

BETHESDA, Md--Concerned that a New England Journal of Medicinearticle reporting no link between fat intake and breast cancermight deter women from joining the diet-cancer segment of theNIH-sponsored Women's Health Initiative (WHI), its top leaderstook an unusual step.

They issued a press statement that challenges, not the article'sfindings, but the notion that the question of whether dietaryfat contributes to the development of breast cancer can be answeredoutside of a randomized clinical trial.

"Numerous other studies . . . support such a link,"the statement said. "The WHI trial is designed to answerconfidently this and other important questions related to women'shealth."

The article, which appeared in the February 8, 1996, issue ofthe Journal and garnered extensive media attention, detailed areanalysis of seven cohort studies that had investigated the linkbetween fat and breast cancer. The studies involved a total of337,819 women.

"We found no evidence of a positive association between totaldietary fat intake and the risk of breast cancer," said leadauthor David J. Hunter of the Harvard School of Public Health."There was no reduction in risk even among women whose energyintake from fat was less than 20% of total energy intake."

The article noted, and the WHI statement emphasized, that othertypes of studies have reached contrary conclusions. These includeepidemiologic studies, comparisons of women living in one countrywith those from that country who have migrated to another andchanged their diet, case-control studies, and animal feeding trials.

This leads to the possibility that the new findings might resultfrom some defect within cohort studies themselves, the WHI statementsaid. In cohort studies, the amount of fat is estimated priorto the development of a breast tumor; in case-control studies,the estimate comes after the cancer appears. Cohort studies generallyget the nod over case-control studies as the more reliable. However,"neither of these types of studies is as reliable as a clinicaltrial," the WHI said.

In an interview with Oncology News International, WHI directorDr. Loretta Finnegan and Dr. Jacques Rossouw, WHI's lead projectofficer, acknowledged their concern that women who heard aboutthe conclusions of the cohort reanalysis might refuse to joinWHI's study.

"Women might be advised by their physicians that it's notworth participating in the trial because it's not likely to succeed,"Dr. Rossouw said. "We don't agree. We think there is a reasonablystrong hypothesis that changing the diet will lower cancer risks."

Dr. Finnegan emphasized that the final word on the subject shouldbe based on "what we call the gold standard, which is theclinical trial, which is the WHI trial."

More than 16,000 women, aged 50 to 79, have enrolled in the dietarycomponent of the WHI at 40 clinical centers nationwide; officialshope that 48,000 will sign up before enrollment ends early in1998. The women will be followed for 9 years.

"What we're testing is whether a total dietary pattern, whichincludes reduction in dietary fats but also increases in fruits,vegetables, and grains, has health benefits for preventing breastcancer, colorectal cancer, and heart disease," Dr. Rossouwsaid.

Women can obtain information on participating in the WHI dietarystudy by calling 1-800-54-WOMEN.

Articles in this issue

Drug Allows Higher Doxorubicin Doses in Breast Ca Patients
Nori Appointed to Cornell Department of Radiation Oncology
Academic Centers Must Change or Perish in Climate of Managed Care
Genetically Altered Hematopoietic Cells Used in Transplant Research
Bill Would Ease Distribution of Off-Label Data
New Critical Pathway Reduces the Costs of Radical Prostatectomy at Chicago Hospital

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 17th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 17th 2025
Podcast

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 17th 2025
Article

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 17th 2025
Podcast

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 17th 2025
Article

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Ariana Pelosci
September 17th 2025
Article
Related Content

ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 17th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 17th 2025
Podcast

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 17th 2025
Article

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 17th 2025
Podcast

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 17th 2025
Article

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Ariana Pelosci
September 17th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.